×

Geminiviral vector for expression of rituximab

  • US 10,125,373 B2
  • Filed: 01/22/2014
  • Issued: 11/13/2018
  • Est. Priority Date: 01/22/2013
  • Status: Active Grant
First Claim
Patent Images

1. A vector comprising a long intergenic region (LIR) of a geminivirus genome, followed by two nucleic acid segments followed by a short intergenic region (SIR) of a geminivirus genome, followed by one or more nucleic acids encoding Rep and RepA proteins of a geminivirus genome, followed by a LIR, wherein the two nucleic acid segments comprise:

  • (a) a nucleic acid segment comprising at least one promoter, a 5′

    UTR, a region encoding a heavy chain of Ritixumab, and a 3′

    terminator; and

    (b) a nucleic acid segment comprising at least one promoter, a 5′

    UTR, a region encoding a light chain of Ritixumab, and a 3′

    terminator;

    wherein the two nucleic acid segments comprise a single replicon.

View all claims
  • 4 Assignments
Timeline View
Assignment View
    ×
    ×